Our pipeline of drug candidates has been developed and progressed by our Innovation Platform, Hutchison MediPharma, which was established in 2002.
Since then, we have assembled a leading drug research and development team of over 330 scientists and staff to create a large scale and fully-integrated drug discovery and development operation covering chemistry, biology, pharmacology, toxicology, chemistry and manufacturing controls for clinical and commercial supply, clinical and regulatory and other functions, which work seamlessly together.
We have created a broad pipeline of drug candidates.
We have taken a chemistry-focused approach to develop highly selective small molecule tyrosine kinase inhibitors that are intended to have potentially global best-in-class efficacy and are deliberately engineered to improve drug exposure and reduce known class-related toxicities. Our current drug candidates may have the potential to be either global first-in-class therapies or be sufficiently differentiated to potentially be global best-in-class, next generation therapies with a superior profile compared to existing approved drugs that act against the relevant kinase targets.